Kiora Pharmaceuticals Inc. (KPRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2024 | 09-2024 | 06-2024 | 03-2024 | 12-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 3,595 | 7,818 | 11,232 | 13,453 | -12,514 |
| Depreciation Amortization | 123 | 118 | 11 | 5 | 52 |
| Income taxes - deferred | -289 | N/A | N/A | N/A | 90 |
| Accounts payable and accrued liabilities | 226 | 451 | 66 | 125 | -808 |
| Other Working Capital | 3,666 | 1,563 | -1,792 | -174 | -1,822 |
| Other Operating Activity | 1,238 | 862 | 374 | 215 | 5,445 |
| Operating Cash Flow | $8,559 | $10,812 | $9,891 | $13,625 | $-9,557 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -6 | -51 | -51 | N/A | N/A |
| Purchase Of Investment | -35,632 | -29,094 | -21,289 | 0 | N/A |
| Sale Of Investment | 12,976 | 6,000 | 116 | 0 | N/A |
| Investing Cash Flow | $-22,663 | $-23,145 | $-21,225 | $0 | $N/A |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 1,689 | 1,689 | 1,689 | 1,439 | N/A |
| Other Financing Activity | 13,809 | 13,809 | 13,809 | 13,809 | 5,966 |
| Financing Cash Flow | $15,498 | $15,498 | $15,498 | $15,248 | $5,966 |
| Exchange Rate Effect | -57 | 18 | -44 | -51 | 36 |
| Beginning Cash Position | 2,459 | 2,459 | 2,459 | 2,459 | 6,014 |
| End Cash Position | 3,796 | 5,642 | 6,580 | 31,280 | 2,459 |
| Net Cash Flow | $1,337 | $3,183 | $4,121 | $28,822 | $-3,555 |
| Free Cash Flow | |||||
| Operating Cash Flow | 8,559 | 10,812 | 9,891 | 13,625 | -9,557 |
| Capital Expenditure | -6 | -51 | -51 | N/A | N/A |
| Free Cash Flow | 8,553 | 10,760 | 9,840 | 13,625 | -9,557 |